-
Rucotinib combination therapy provides a new solution for the treatment of intolerant or drug-resistant MF patients
Time of Update: 2021-10-21
Figure 2 The results of the study on the proportion of patients with different daily doses show that the rucotinib dosage regimen has a significant effect on spleen shrinkage and symptom improvement in patients with anemic MF.
-
Nat Med: The prevalence of anemia among women of childbearing age in low- and middle-income countries from 2000 to 2018
Time of Update: 2021-10-20
In this study, researchers aimed to map the prevalence of anemia in women of childbearing age (15-49 years old) in 82 low- and middle-income countries from 2000 to 2018 Annual geospatial estimate of the rate, and stratification of anemia by severity and summary results .
-
Neurology: Serum S100B concentration as a substitute outcome parameter after mechanical thrombectomy
Time of Update: 2021-10-20
Recently, an authoritative journal in the field of neurology published a research article in Neurology, which aims to clarify the serum S100B protein concentration as an objective biomarker of astrocyte tissue damage after mechanical thrombus removal in patients with acute ischemic stroke .
-
AJH: Comparison of the incidence of second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia
Time of Update: 2021-10-20
In order to specifically assess the impact of CLL-guided treatment on the incidence of SPM, a foreign research team analyzed a comprehensive data set of treated and untreated patients registered by the German CLL Research Group (GCLLSG) and published it in the journal AJH .
-
J Clin Oncol: Ibrutinib combined with Venetog as the first-line treatment of chronic lymphocytic leukemia has a good prognosis
Time of Update: 2021-10-20
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study .
-
Does your hospital carry out these special blood tests?
Time of Update: 2021-10-20
Red blood cell incubation osmotic fragility test significance This test is sensitive to the detection of mild hereditary spherocytosis, and is also seen in pyruvate kinase deficiency and other enzyme-deficient hemolytic anemia .
-
AJH: The effect of plasma non-transferrin-bound iron on systemic iron overload and intravenous iron supplementation
Time of Update: 2021-10-20
Non-transferrin bound iron (NTBI) has been classically used to represent potentially toxic plasma components detected in whole body iron overload, and is related to end-organ iron accumulation and biological damage .
-
BLOOD: Effective treatment of AML with RUNX1 mutation by co-treatment with protein translation inhibitor and bcl2
Time of Update: 2021-10-20
Compared with each drug alone, ometacin and venetoclax or BET inhibitor The combination therapy also showed improved anti-AML efficacy in vivo Currently, the ELN classification of AML prognostic subtypes designates AML with mtRUNX1 as a temporary entity related to poor prognosis .
-
AJKD: The humoral and cellular responses of hemodialysis patients to mRNA-1273 and BNT162b2 SARS-CoV-2 vaccine
Time of Update: 2021-10-20
Compared with the general population, patients with renal failure who are undergoing maintenance dialysis are at higher risk of contracting new coronary pneumonia and have worse clinical outcomes after infection .
-
Ann Hematol: Quality of life of survivors one year after diagnosis of diffuse large b-cell lymphoma: a LYSA study
Time of Update: 2021-10-20
Reduce the number of cycles of chemotherapy (ie All in all, studies have shown that there are differences in HRQoL between female and male survivors one year after diagnosis of lymphoma, and women are more likely to experience post-traumatic growth and decline in physical function than men .
-
HAEMATOLOGICA: Ibrutinib treatment fails to induce the clonal evolution of TP53 in chronic lymphocytic leukemia
Time of Update: 2021-10-20
In CLL patients with TP53 mutations, ibrutinib in any treatment regimen reduces the complexity of TP53 for at least the first few years of treatment, and unlike CIT, it does not impose positive selection on existing TP53 mutant clones.
-
BJH: Conflict influence of tocilizumab and colchicine in coagulation associated with new coronavirus pneumonia
Time of Update: 2021-10-20
The benefit of TCZ in covid-19 patients may be due to the discovery that antibodies can only partially inhibit IL-6-mediated inflammatory activity (7) and fail to prevent the release of α-Def and subsequent increase in coagulation acceleration represented by d-dimer .
-
Ann Hematol: Molecular genetics and clinicopathological characteristics of thymic MALT lymphoma
Time of Update: 2021-10-20
A foreign research team investigated the clinicopathological characteristics of 11 cases of thymic MALT lymphoma from a single center .
A foreign research team investigated the clinicopathological characteristics of 11 cases of thymic MALT lymphoma from a single center .
-
Nat Med: Analysis of the efficacy of dual targeting CART cells in children and young adults with relapsed or refractory B-ALL
Time of Update: 2021-10-20
The secondary endpoints include morphological remission rate (complete remission or complete remission with incomplete bone marrow recovery) And minimal residual disease negative reactions, as well as the frequency and severity of adverse events, the expansion and persistence of AUTO3, the duration of B cell hypoplasia, and overall and event-free survival .
-
Aspaveli (pegcetacoplan) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), has received positive opinions from EU CHMP
Time of Update: 2021-10-19
Blood vessel Apellis Pharmaceuticals announced today that the European Medicines Management Agency Committee medicines for human use (CHMP) has adopted a positive recommendation that Aspaveli (pegcetacoplan) listed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in adult patients, these patients Anemia occurred after receiving C5 inhibitor treatment for at least three months .
-
BLOOD: Targeted membrane-bound anionic phospholipid anticoagulation therapy can improve the outcome of traumatic brain injury in mice
Time of Update: 2021-10-19
Their research article was published in the journal BLOOD, Severe Traumatic Brain Injury TBI Severe Traumatic Brain Injury TBI Here, they showed the results of a study designed to test anticoagulation against EVs expressing anionic phospholipids The agent prevents TBI-IC and improves the outcome hypothesis in mice suffering from severe TBI .
-
Lancet oncol: Phase 3 daratumumab + lenalidomide first-line treatment of multiple myeloma not suitable for transplantation can be expected!
Time of Update: 2021-10-19
0 months), daretal was used compared with newly diagnosed multiple myeloma patients who were not eligible for transplantation treated with lenalidomide and dexamethasone The progression-free survival of patients treated with yuumab combined with lenalidomide and dexamethasone was significantly prolonged .
-
AJH: Hyperoxia-affinity hemoglobinopathies-associated polycythemia: 41 cases of clinical outcome and treatment impact
Time of Update: 2021-10-19
The current study did not imply Hgb / Hct hemoglobin level is increasing HOA correlation between cell anemia disease incidence of major contributors, and demonstrated the value of limited bloodletting treatment of heart vascular Prevention recommend close monitoring of patients with cardiovascular risk factors Hb / Hct Value .
-
Lancet Haemat: The safety of intratumoral injection of TTI-621 in the treatment of relapsed or refractory mycosis fungoides or Sézary syndrome
Time of Update: 2021-10-19
In summary, for patients with relapsed or refractory mycosis fungoides or Sézary syndrome, intratumoral injection of TTI-621 is well tolerated, and anti-tumor activity is detected in adjacent or distal non-injected lesions, suggesting TTI-621 has systemic and local remote effects, and has the potential as an immunotherapy for these diseases .
-
CCSC: From research to practice, the application of CAR-T in the treatment of lymphoma
Time of Update: 2021-10-11
Professor Lin Yi briefly introduced the current regulatory standards of CAR-T therapy in the United States and the FDA's risk assessment and mitigation strategy (REMS), and then demonstrated the entire management of CAR-T therapy through a real case, combined with ZUMA-1 Research and a number of real-world studies illustrate the screening strategies of patients and the effective management of adverse events when CAR-T is applied in the real world .
